GL1X · GenesisL1 explorer

MolNFT v1 · #10807 · protein

Creatininase zn

1J2U · Creatinine amidohydrolase: “Creatininase zn”. X-ray diffraction, 2 ligands (ZN, SO4), 20 pockets (best druggability 0.84). MolNFT v1 #10807 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
1J2U
Type
protein
Length
1,542 residues
Chains
6
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Creatinine amidohydrolase
EC
3.5.2.10
UniProt
P83772
Ligands
ZN, SO4
Pockets
20 · best druggability 0.84

Structure

x-ray diffraction · 1 distinct chain · 48% helix, 12% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, C, D, E, FCreatinine amidohydrolase (EC 3.5.2.10)protein25748% helix, 12% strandP83772

Ligands and binding sites

  • ZN · Zinc ion · metal · 12 copies · chains A, B, C, D, E, F
  • SO4 · Sulfate ion · ion · 10 copies · chains A, B, C, D, E, F

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 14 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110650.840.8597ZN
210670.840.8595ZN
310840.840.84101ZN
48780.800.8380empty
5600.750.9914empty

Interfaces

12 interfaces between chains.

  • B–C · 1964 Ų buried · 47 hydrogen bonds · protein-protein
  • D–E · 1949 Ų buried · 42 hydrogen bonds · protein-protein
  • A–F · 1930 Ų buried · 45 hydrogen bonds · protein-protein
  • A–B · 1494 Ų buried · 34 hydrogen bonds · protein-protein
  • C–D · 1478 Ų buried · 32 hydrogen bonds · protein-protein

Compared structures

  • 1J2U · Creatininase Zn · the same entry in another collection · chain F against F, TM-score 1.00
  • P83772 · AlphaFold monomer V2.0 prediction for creatinine amidohydrolase (P83772) · a predicted model of the same protein · chain E against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.